Checkpoint Therapeutics Stock Price, News & Analysis

Checkpoint Therapeutics (NASDAQ: CKPT) announced promising outcomes from its clinical trial of cosibelimab for metastatic cutaneous squamous cell carcinoma (cSCC). The study achieved a primary endpoint with a 47.4% objective response rate. Safety results remain consistent with prior data, indicating manageable adverse events. A Biologics License Application (BLA) submission to the FDA is planned for later this year. The company aims to offer cosibelimab at a lower price compared to existing PD-(L)1 therapies, which may enhance market share. The ongoing study suggests significant potential for future market growth.

Checkpoint Therapeutics (CKPT) has launched the CONTERNO study, a global Phase 3 trial assessing cosibelimab combined with chemotherapy for treating non-squamous non-small cell lung cancer (NSCLC). The trial aims to enhance overall survival in patients and support worldwide regulatory approvals. With 1.7 million new NSCLC cases reported in 2020, the study focuses on potentially improving patient outcomes. The primary endpoint is overall survival, while key secondary endpoints include progression-free survival and safety, involving approximately 560 subjects.

Checkpoint Therapeutics (NASDAQ: CKPT) announced its third-quarter financial results for 2021, highlighting a net loss of $11.3 million, or $0.14 per share, compared to a loss of $4.9 million, or $0.09 per share in Q3 2020. R&D expenses surged to $9.4 million, up from $2.5 million in the prior year, primarily due to costs associated with cosibelimab trials. Cash reserves decreased to $60.2 million, down $4.9 million from the previous quarter. The company aims for a Biologics License Application for cosibelimab next year and is advancing a Phase 3 trial for non-small cell lung cancer.

Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021, at 9:20 a.m. ET. The company’s management will also hold one-on-one meetings during the event. A live webcast of the chat will be available on Checkpoint's website for 30 days post-event. Checkpoint focuses on developing immunotherapy and targeted oncology treatments, including its lead antibody candidate, cosibelimab, currently undergoing a Phase 1 clinical trial.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announces participation of CEO James Oliviero in two investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, available on-demand at 7 a.m. ET. The second is Lake Street’s 5th Annual Best Ideas Growth Conference on September 15, 2021, featuring one-on-one meetings only. Checkpoint, focused on immunotherapy for solid tumors, is evaluating its lead candidates, including cosibelimab and CK-101.

Checkpoint Therapeutics (CKPT) reported its Q2 2021 financial results, highlighting key advancements in its clinical pipeline. The company completed patient enrollment for its pivotal trial of cosibelimab, an anti-PD-L1 antibody, and expects top-line data by Q4 2021, aiming for a BLA submission in 2022. Checkpoint's cash position improved to $65.1 million, up from $60 million in Q1. However, R&D expenses rose significantly to $7.2 million, contributing to a net loss of $9.1 million, or $0.12 per share, compared to $4.6 million, or $0.09 per share, in Q2 2020.

Checkpoint Therapeutics (NASDAQ: CKPT) announced that CEO James Oliviero will speak at the Ladenburg Thalmann 2021 Healthcare Conference on July 13-14, 2021. The company will present a corporate update on July 14 at 11:30 a.m. ET and engage in one-on-one meetings. A webcast of the presentation will be available for 30 days on their investor website. Checkpoint focuses on developing novel cancer treatments, notably its lead product cosibelimab, an anti-PD-L1 antibody, and CK-101, an EGFR inhibitor for lung cancer. For more details, visit www.checkpointtx.com.

Checkpoint Therapeutics, Inc. (CKPT) announced the completion of patient enrollment in its registration-enabling clinical trial for cosibelimab targeting metastatic cutaneous squamous cell carcinoma (cSCC). Top-line results are anticipated in 4Q 2021, with a Biologics License Application (BLA) submission planned for 1H 2022. Cosibelimab aims to disrupt the $25 billion PD-(L)1 market with competitive pricing and a favorable safety profile, aiming for rapid market adoption. The company also expects to include data on locally advanced cSCC in its upcoming submissions.

Checkpoint Therapeutics (NASDAQ: CKPT) reported its Q1 2021 financial results, highlighting advancements in drug development and a strengthened cash position. Cash and cash equivalents increased to $60 million, up from $40.8 million at year-end 2020. R&D expenses rose to $4.2 million, while G&A expenses climbed to $2.4 million. The net loss for Q1 2021 was $6.5 million, or $0.09 per share, compared to a loss of $3.3 million, or $0.06 per share, in Q1 2020. Enrollment in a pivotal study for cosibelimab is nearing completion, with results expected by year-end.